GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Harbour Solutions launches SEER pilot to leverage AI-powered building intelligence
SEER platform combines semantic building knowledge, real-time analytics and AI to help building operators make faster decisions, improve maintenance efficiency ...
When should founders bring in a board and why it matters
A well-functioning board brings external expertise, different perspectives and strategic oversight.
‘The issue runs much deeper than many realise’ – James Vella Clark on TCN Budget measures
The Budget has scrapped free public transport and free childcare benefits for certain categories of TCNs.
Azzopardi Group and Salv Group launch Malta’s first Buddha-Bar
Joseph Azzopardi says their vision was to bring something truly special to Malta.
